CVSC: CVSC is fully aware of the baby boomer market out there that continues to grow!
There will be 57.8 million baby boomers living in 2030 according to projections.
Many baby boomers will need orthopedic surgery.
A study by Exponent projected a 673-percent increase in knee replacement surgeries over the next 25 years. Primary or revision knee replacements are expected to balloon to more than 3.5 million by 2031!
CVSC knows that the currently available products on the market for adhesions are not sufficiently effective, and are difficult and very costly to use.
CVSC is developing products that will be markedly more effective at a lower cost, and will also provide easier handling for the surgeons.
CVSC owns technology in a variety of other areas, including thrombo-resistant coatings, enhanced intra-arterial balloon pumping catheters, cell engineered vascular tissues, and a method for improved recovery of the heart following cardioplegia.
CVSC has the worldwide marketing and licensing rights for a patented process that provides a novel cardioplegia solution containing pyruvate for use in cardiopulmonary bypass surgery.
Administration of the cardiplegia solution during surgery has numerous beneficial effects: 1) It protects the heart from injury resulting from ischemia; 2) the heart exhibits rapid and robust recovery. This process can also be used during valve replacement and repairs of structural defects of the heart.
CVSC has also acquired the rights to develop and market four patented aortic pumping catheters: an Enhanced Intra-Aortic Balloon Catheter (EIABC), a Removable Left Ventricular Assist Device with an Aortic Support Apparatus, a Coronary Artery Counterpulsation Device and Method, and a Piston-action Intra-Aortic Coronary Assist Device. The new catheter designs overcome the inefficiencies of existing products in the market, and are designed to be application specific, thereby delivering the optimal performance for any given clinical setting.
Currently, there are more than 600,000 cardiac catheterization procedures performed annually in the United States. There are more than 2.5 million cardiac catheterization procedures performed annually and as many as twice that as a global total.
CVSC has sponsored research at the University of Central Florida (UCF) and previously at other institutions which indicates that CVSC is on the right path and progressing well.
CVSC and the University of Central Florida have entered into an agreement to research and develop post-surgical anti-adhesion materials. The principal investigator, Dr. Kevin Belfield, chairman of the Department of Chemistry, is leading a team to further develop the most effective and efficient anti-adhesion materials.
It is expected that the scope of this research will expand and broaden as CVSC continues to develop this technology.
CVSC and the University of Central Florida have produced a second-generation material with physical properties which appear to have exceeded the initially designed criteria. At surgery, this material is placed over and between areas likely to produce adhesions and are gradually degraded and resorbed by the body after the period in which adhesions are likely to occur, has passed.
CVSC's next phase in development will involve several areas of investigation. One will be to devise methods to manipulate the physical characteristics of the material in order to broaden the range of indications in which the material will be useful. A second will be to expand the animal trials beyond the proof-of-concept phase so that data can be gathered to support the requirements to bring this product to market, first in the veterinary arena and on to use in human clinical medicine.
(level2stockquotes.com)
News 
Market Data 
Discover 
AI
